Skip to main content

Patient Representative Committee

Patient Representative Committee
The patient voice in clinical trial research

Canadian Cancer Trials Group (CCTG) recognizes the value and importance of engaging patients, including the patient voice in all aspects of the clinical trial life-cycle. Integrating the patient perspective into the CCTG’s overall strategic agenda ensures the research agenda has the greatest impact on cancer patients in Canada and around the world.

CCTG has implemented a model of dedicated public and patient involvement by including the Patient Representative, who are patient volunteers recruited to disease site committees similar to academic committee members with a three year extendable term.

  • The role of the CCTG Patient Representative has evolved to integrate the patient perspective into many steps of the research process with the aim of:
    • research questions that matter to patients, and
    • improved accrual
  • CCTG is committed to implementing best practices and materials to foster and facilitate patient engagement

If you are looking for more information about the CCTG Patient Representative Committee please contact Yvonne Murray, Patient Engagement Lead for information.

CCTG is currently looking for volunteers for the following role:

For more information about committee openings please contact Nancy Dusharm.

Priorities in cancer research

CCTG Patient Representatives participated in a facilitated workshop session to identify six research topics most important to cancer patients and caregivers. For the results >

CCTG Patient Representative Committee

Michelle Audoin CCTG Patient Representative Committee Chair

Michelle Audoin 
Committee Chair & Health Equity

Emi Bossio
Emi Bossio
Thoracic
Bill Richardson

Bill Richardson
Head & Neck 
GenitoUrinary

Hilary Horlock

Hilary Horlock
Supportive Care & QoL

Catherine Wreford

Catherine Wreford
Brain & CSTB

Lindsay Clarke

Lindsay Clarke
Genitourinary

SallyNystrom

Sally Nystrom
Melanoma & Skin

Louise Bird

Louise Bird
DSMC

Jasmine Heuring

Jasmine Heuring
CEA, AYA & Sarcoma

Lesley Beaton

Lesley Beaton
Gastrointestinal

Darren Frew CCTG Patient Representative

Darren Frew 
Gastrointestinal

Carol Hill

Carol Hill
IND program

Deb Clarke

Deb Clark
DSMC

Ruth Ackerman

Ruth Ackerman
Breast

Dawn Barker

Dawn Barker
Breast

Catherine Caule

Catherine Caule
Hematology

Tracy Kitz

Tracy Kitz
Hematology

Melanie Keats

Melanie Keats
Gynecology

 

 

 

 

 

 

 

Now open, the SC30 study investigating the role of immunoglobulin and antibiotics on infections in patients with blood cancers

Now open, the SC30 study investigating the role of immunoglobulin and antibiotics on infections in patients with blood cancers

enrollment of the first patient in the third substudy IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC)

First Patient Enrolled in New Sub-study in Ovarian Cancer Immunotherapy Platform Trial

Terri and Alison at the gym - CO21 clinical trial

Landmark Clinical Trial Shows Exercise Improves Colon Cancer Survival 

Seeking Patient Representative for the Breast Disease Site Committee

Seeking Patient Representative for the Breast Disease Site Committee

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Breast Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse national network, so we are strongly considering applications for patient representation from Quebec, New Brunswick, Nova Scotia, PEI or Newfoundland and Labrador for this position.

More >>
 
New study SC31 TEMPO testing an online program to support people with prostate cancer and their caregivers

The new SC31 TEMPO study is testing an online support program for people with prostate cancer and their caregivers

The SC31 TEMPO trial is now open and evaluating an innovative online program designed to help people with prostate cancer and their caregivers better manage the physical and emotional challenges associated with cancer and its treatment.

More >>
 
Patient Represenative Melanie Keats

Welcome to new Patient Represenative Melanie Keats

CCTG would like to welcome Melanie Keats as the new patient representative supporting the Gynecologic Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.

More >>
 
June is National Indigenous History Month and Pride Month

CCTG recognizes June as National Indigenous History Month and Pride Month

June marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities. It is also an opportunity to reflect on our shared responsibility to advance equitable, inclusive, and culturally safe clinical trial design and conduct.

More >>